



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 14 Feb 2023 (#07)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Important Notices

[NOT-OD-23-080](#) Clinical Trials Results Information Submission: Good Cause Extension Request Process and Criteria Document Posted on ClinicalTrials.gov. The purpose of this Notice is to inform the research community that NIH has issued the "[Clinical Trials Results Information Submission: Good Cause Extension Request Process and Criteria](#)" outlining the process and criteria for requesting a good cause extension of the submission deadline for clinical trial results information (Good Cause Extension request) under [42 CFR 11.44\(e\)](#) of the Final Rule for Clinical Trials Registration and Results Information, ([Final Rule](#)), section [402\(j\)\(3\)\(E\)\(vi\)](#) of the Public Health Service (PHS) Act, and the complementary NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information ([NOT-OD-16-149](#)) (complementary policy). First Estimated Application Due Date: May 04, 2023.

[NOT-DK-23-012](#) Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional). The purpose of this Notice is to inform the community that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to publish a Funding Opportunity Announcement (FOA) that will solicit broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK mission areas. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This will be an open competition. Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply.

[NOT-NS-23-035](#) Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed). The purpose of this notice is to inform applicants of the intention to re-issue [RFA-NS-21-026](#) and [RFA-NS-21-027](#), which were recently terminated. This Notice is being provided to alert potential applicants of anticipated changes in receipt dates and updated information on FOA requirements and goals. Previously, both [RFA-NS-21-026](#) and [RFA-NS-21-027](#) included support for molecular constructs for recording and manipulating neural activity. However, **with the re-issued FOAs, projects primarily focused on molecular technologies will only be supported by the reissue of RFA-NS-21-026.** Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply. First Estimated Application Due Date: June 30, 2023.

[NOT-NS-23-036](#) Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed). The purpose of this notice is to inform applicants of the intention to re-issue [RFA-NS-21-026](#) and [RFA-NS-21-027](#), which were recently terminated. This Notice is being provided to alert potential applicants of anticipated changes in receipt dates and updated information on FOA requirements and goals. Previously, both [RFA-NS-21-026](#) and [RFA-NS-21-027](#) included support for molecular constructs for recording and manipulating neural activity. However, *with the re-issued FOAs, projects primarily focused on molecular technologies will only be supported by the reissue of RFA-NS-21-026.* Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply. First Estimated Application Due Date: June 30, 2023.

[NOT-OD-23-081](#) Notice of Intent to Publish a Funding Opportunity Announcement to Reissue RFA-OD-21-002, the Tobacco Regulatory Science (R01 Clinical Trial Optional). This Notice is to inform the research community that the National Institutes of Health (NIH) Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration (FDA) Center for Tobacco Products (CTP) intend to reissue the Funding Opportunity Announcement (FOA) [RFA-OD-21-002 "Tobacco Regulatory Science \(R01 Clinical Trial Optional\)"](#). When reissued, this FOA will continue to utilize the R01 grant mechanism. Modifications to this FOA may include revised research priorities and non-responsive topics. This Notice is being published now to inform prospective applicants in advance of this modification. First Estimated Application Due Date: October 05, 2023. Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply.

Notices of Special Interest (NOSI)

[NOT-HD-23-003](#) Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals. The purpose of this Notice of Special Interest (NOSI) is to encourage research on the processes that facilitate or hinder the achievement of healthy interbirth intervals and promote healthy birth outcomes. This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2024. Submit applications for this initiative using one of the FOAs listed in the notice or any reissues of these announcements.

[NOT-NS-23-062](#) Advancing Research for Amyotrophic Lateral Sclerosis (ALS). The purpose of this NOSI is to announce that the National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to [strategic priorities for the ALS research community](#) identified in a recent planning effort of NINDS. PIs planning to submit applications are strongly encouraged to contact NINDS scientific program staff when developing their projects. This notice applies to due dates on or after March 14, 2023, and subsequent receipt dates through June 24, 2024. Submit applications for this initiative using one of the FOAs listed in the notice or any reissues of these announcements.

[NOT-OD-23-042](#) Discovery of the Genetic Basis of Conditions Associated with Down Syndrome for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project (X01) Down syndrome is the most common genetic cause of intellectual disability, the most common autosomal trisomy, and one of the most visible and universally recognized genetic syndromes. This FOA is one of several trans-NIH research initiatives created in response to Fiscal Year 2018, 2019, 2020, 2021 and 2022 Omnibus Appropriations Reports, which encourage NIH to expand its current efforts on Down syndrome and common co-occurring conditions also seen in the general population, while increasing the pipeline of Down syndrome investigators. The purpose of this NOSI is to support the whole genome and other sequencing of cohort projects that seek to elucidate the genetic etiology of conditions that co-occur with Down syndrome and that meet programmatic objectives for the INCLUDE Project. This notice applies to due dates on or after March 21, 2023 and subsequent receipt dates through March 22, 2023.

[NOT-OD-23-070](#) Administrative Supplements to Support the Exploration of Cloud in NIH-supported Research. This notice announces the availability of supplemental funds from the Office of Data Science Strategy (ODSS) to NIH-managed or NIH-majority-funded projects that may benefit from using the cloud. The purpose of this announcement is to explore and test potential opportunities for leveraging cloud solutions to enhance existing NIH activities. Projects

already using cloud may apply to explore and test cloud capabilities not yet leveraged. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at building a better data infrastructure and a modernized data ecosystem. To be eligible, the parent award must be able to receive funds in FY2023 (Oct. 1, 2022 - Sept. 30, 2023). Applicants are strongly encouraged to contact the program officer of the parent award to confirm eligibility. The total requested budget cannot exceed \$150K direct cost including cloud resources. Application Due Date Apr. 11, 2023, by 5:00 PM local time of applicant organization. Requests may be for one year of support only, and the proposed budget period cannot exceed that of the parent award. The Research Strategy section of the application is limited to 4 pages including any diagrams. The applicants must have obtained the necessary documents including but not limited to IT security certificate and/or data regulatory approval and/or other policy approval in order to perform the proposed work prior to the submission if applicable. It is strongly recommended that the applicants contact their respective program officers at the Institute supporting the parent award in advance to:

- Confirm that the supplement falls within scope of the parent award
- Request the requirements of the IC for submitting applications for administrative supplements

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-035](#)

Type: X01

Application Due Date: March 21, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: As part of the Gabriella Miller Kids First Pediatric Research Program ([Kids First Program](#)), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the [Kids First Data Resource](#). The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing [Kids First Program projects](#). These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 1 year. Investigators are expected to ship samples to designated Kids First Program's sequence center within 6 months of the award notification. This period may be extended only in exceptional cases upon justification and approval.

2. NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-090](#)

Type: UG3/UH3

Application Due Date: June 06, 2023 through to . March 06, 2026 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN

Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The typical project period is 5 years. The UG3 phase is a maximum of 2 years and UH3 phase a maximum of 5 years. Should a project require more than five years of support, special permission should be requested from NINDS prior to submission of the grant.

3. Comparative Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging-Related Outcomes, and Prospects for Translation (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-019](#)

Type: R01

Application Due Date: September 27, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites R01 applications proposing comparative studies of human and nonhuman primate species with differing life spans to identify factors whose cross-species variation may contribute to differences in species life span and health span, including, but not limited to, factors contributing to humans' greater life span compared to other primates. Studies that involve primary in vivo or in vitro data generation and/or analyses of existing data or biospecimens are encouraged. Factors of interest include genetic, molecular, physiological, neurological and behavioral traits. This FOA requests applications that propose studies to elucidate the relationship of such factors to primate species life span differences, and mechanisms that may mediate such relationships. These projects may also include research to identify potential human therapeutic targets and interventions that modulate mechanisms implicated by the comparative studies.

Budget: NIA intends to commit up to \$4.5 million in fiscal year 2024 to fund approximately 6 awards, contingent on funding availability. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Sexually Transmitted Infections (STI) Cooperative Research Centers (CRC): Vaccine Development (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-008](#)

Type: U01

Application Due Date: June 14, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to advance vaccine candidates for gonorrhea, chlamydia and syphilis by supporting IND-enabling activities. Applications must include a Product Development Strategy.

Budget: NIAID intends to commit \$8.4M in FY 2024 to fund 2 to 3 awards. Application budgets are not expected to exceed \$1.4M in direct costs per year and should reflect the actual needs of the project. The scope of the proposed project should determine the project period. The maximum project period is five years.

5. Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-027](#)

Type: R25

Application Due Date: February 08, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support training and educational activities for responsible analyses of complex large-scale data involving brain, behavioral, genomic, and socioenvironmental data that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs.

- **Courses for Skills Development**
- **Curriculum or Methods Development**

Budget: NIDA intends to commit \$1.5 million in FY 2024 to fund up to 4 awards. Application budgets must reflect the actual needs of the proposed project and are limited to \$300,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 3 years..

6. Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-037](#)

Type: R21

Application Due Date: March 07, 2023 through to November 15, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.

Budget: NIDA intends to commit \$2 million in FY2023, FY2024 and FY2025, to fund 4-6 awards each year. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum period is 2 years.

Research Development and Support Division (RDSD) &
Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105